Literature DB >> 16899222

The regulation of adiponectin receptors in human prostate cancer cell lines.

T Mistry1, J E Digby, J Chen, K M Desai, H S Randeva.   

Abstract

Obesity is a risk factor for prostate cancer, and plasma levels of the adipokine, adiponectin, are low in the former but high in the latter. Adiponectin has been shown to modulate cell proliferation and apoptosis, suggesting that adiponectin and its receptors (Adipo-R1, Adipo-R2) may provide a molecular association between obesity and prostate carcinogenesis. We show for the first time, the protein distribution of Adipo-R1 and Adipo-R2 in LNCaP and PC3 cells, and in human prostate tissue. Using real-time RT-PCR we provide novel data demonstrating the differential regulation of Adipo-R1 and Adipo-R2 mRNA expression by testosterone, 5-alpha dihydrotestosterone, beta-estradiol, tumour necrosis factor-alpha, leptin, and adiponectin in LNCaP and PC3 cells. Our findings suggest that adiponectin and its receptors may contribute to the molecular association between obesity and prostate cancer through a complex interaction with other hormones and cytokines that also play important roles in the pathophysiology of obesity and prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899222     DOI: 10.1016/j.bbrc.2006.07.139

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Adiponectin receptors are downregulated in human gastric cancer.

Authors:  Kensuke Otani; Joji Kitayama; Takao Kamei; Daisuke Soma; Hideyo Miyato; Toshimasa Yamauchi; Takashi Kadowaki; Hirokazu Nagawa
Journal:  J Gastroenterol       Date:  2010-03-25       Impact factor: 7.527

Review 2.  Adiponectin as a Potential Therapeutic Target for Prostate Cancer.

Authors:  Hanuma Kumar Karnati; Manas Kumar Panigrahi; Yazhou Li; David Tweedie; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 3.  Multifaceted roles of adiponectin in cancer.

Authors:  Lionel Hebbard; Barbara Ranscht
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-11-22       Impact factor: 4.690

Review 4.  Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Authors:  Aimalie L Hardaway; Mackenzie K Herroon; Erandi Rajagurubandara; Izabela Podgorski
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  Genetic analysis of ADIPOQ variants and gastric cancer risk: a hospital-based case-control study in China.

Authors:  Lei Ye; Zuo-Yang Zhang; Wei-Dong Du; Marion E Schneider; Yue Qiu; Yuan Zhou; Fu-Sheng Zhou; Xian-Bo Zuo; Gang Chen; Xue-Ling Ma; Hong-Zhen Xia; Song Xu; Ji-Feng Wu; Hong-Yuan Xu; Xue-Jun Zhang
Journal:  Med Oncol       Date:  2013-07-25       Impact factor: 3.064

6.  Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer.

Authors:  Preet K Dhillon; Kathryn L Penney; Fredrick Schumacher; Jennifer R Rider; Howard D Sesso; Michael Pollak; Michelangelo Fiorentino; Stephen Finn; Massimo Loda; Nader Rifai; Lorelei A Mucci; Edward Giovannucci; Meir J Stampfer; Jing Ma
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-29       Impact factor: 4.254

Review 7.  Molecular pathways: adiponectin and leptin signaling in cancer.

Authors:  Michael N Vansaun
Journal:  Clin Cancer Res       Date:  2013-01-25       Impact factor: 12.531

8.  Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression.

Authors:  Eun Shin; Do Joong Park; Hyung-Ho Kim; Nam Hee Won; Gheeyoung Choe; Hye Seung Lee
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-29       Impact factor: 4.553

Review 9.  Adiponectin and colorectal cancer.

Authors:  Kensuke Otani; Soichiro Ishihara; Hironori Yamaguchi; Koji Murono; Koji Yasuda; Takeshi Nishikawa; Toshiaki Tanaka; Tomomichi Kiyomatsu; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa; Toshiaki Watanabe
Journal:  Surg Today       Date:  2016-04-09       Impact factor: 2.549

10.  Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.

Authors:  Jeannette M Schenk; Alan R Kristal; Marian L Neuhouser; Catherine M Tangen; Emily White; Daniel W Lin; Ian M Thompson
Journal:  Prostate       Date:  2009-09-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.